Statement of Principles concerning malignant neoplasm of the ovary (Balance of Probabilities) (No. 10 of 2018)

made under subsection 196B(3) of the

Veterans' Entitlements Act 1986

Compilation No. 1

Compilation date: 2 April 2018

Includes amendments up to: Amendment Statement of Principles concerning malignant neoplasm of the ovary No. 36 of 2018 (F2018L00184)

The day of commencement of this Amendment Statement of Principles concerning malignant neoplasm of the ovary is 2 April 2018.

Prepared by the Repatriation Medical Authority Secretariat, Brisbane
About this compilation

This compilation

This is a compilation of the Statement of Principles concerning malignant neoplasm of the ovary No. 10 of 2018 that shows the text of the law as amended and in force on 2 April 2018.

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

Self-repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Statement of Principles
cconcerning
MALIGNANT NEOPLASM OF THE OVARY
(Balance of Probabilities)
(No. 10 of 2018)

The Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(3) of the Veterans' Entitlements Act 1986.

Dated 22 December 2017

The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:

Professor Nicholas Saunders AO
Chairperson
Contents

1  Name........................................................................................................................................3
2  Commencement ............................................................................................................................3
3  Authority .......................................................................................................................................3
4  Revocation ....................................................................................................................................3
5  Application ...................................................................................................................................3
6  Definitions ....................................................................................................................................3
7  Kind of injury, disease or death to which this Statement of Principles relates ........3
8  Basis for determining the factors .................................................................................................4
9  Factors that must exist ..................................................................................................................4
10 Relationship to service ..................................................................................................................6
11 Factors referring to an injury or disease covered by another Statement of Principles.................6

Schedule 1 - Dictionary ....................................................................................................................7

1  Definitions....................................................................................................................................7
1 Name
This is the Statement of Principles concerning malignant neoplasm of the ovary (Balance of Probabilities) (No. 10 of 2018).

2 Commencement
This instrument commences on 29 January 2018.

3 Authority
This instrument is made under subsection 196B(3) of the Veterans’ Entitlements Act 1986.

4 Revocation
The Statement of Principles concerning malignant neoplasm of the ovary No. 71 of 2009, as amended, made under subsections 196B(3) and (8) of the VEA is revoked.

5 Application
This instrument applies to a claim to which section 120B of the VEA or section 339 of the Military Rehabilitation and Compensation Act 2004 applies.

6 Definitions
The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.

7 Kind of injury, disease or death to which this Statement of Principles relates
(1) This Statement of Principles is about malignant neoplasm of the ovary and death from malignant neoplasm of the ovary.

   Meaning of malignant neoplasm of the ovary

   (2) For the purposes of this Statement of Principles, malignant neoplasm of the ovary:

   (a) means a primary malignant neoplasm arising from the cells of the ovary; and
   (b) includes cell types of borderline malignant potential; and
   (c) excludes soft tissue sarcoma, carcinoid tumour, non-Hodgkin's lymphoma and Hodgkin's lymphoma.

   Note: Most primary malignant ovarian neoplasms are epithelial cancers (carcinomas). Other subtypes include malignant stromal and germ cell tumours.
(3) While malignant neoplasm of the ovary attracts ICD-10-AM code C56 or D39.1, in applying this Statement of Principles the meaning of malignant neoplasm of the ovary is that given in subsection (2).


Death from malignant neoplasm of the ovary

(5) For the purposes of this Statement of Principles, malignant neoplasm of the ovary, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's malignant neoplasm of the ovary.

Note: terminal event is defined in the Schedule 1 – Dictionary.

8 Basis for determining the factors

On the sound medical-scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that malignant neoplasm of the ovary and death from malignant neoplasm of the ovary can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.

Note: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.

9 Factors that must exist

At least one of the following factors must exist before it can be said that, on the balance of probabilities, malignant neoplasm of the ovary or death from malignant neoplasm of the ovary is connected with the circumstances of a person's relevant service:

(1) having endometriosis for at least five years before the clinical onset of malignant neoplasm of the ovary;

(2) having received a cumulative equivalent dose of at least 0.5 sievert of ionising radiation to the ovary at least ten years before the clinical onset of malignant neoplasm of the ovary;

Note: cumulative equivalent dose is defined in the Schedule 1 - Dictionary.

(3) being obese for at least five years within the 20 years before the clinical onset of malignant neoplasm of the ovary;

Note: being obese is defined in the Schedule 1 - Dictionary.
(4) inhaling respirable asbestos fibres in an enclosed space:
   (a) for a cumulative period of at least 2 000 hours before the clinical onset of malignant neoplasm of the ovary; and
   (b) at the time material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled; and
   (c) where the first inhalation of respirable asbestos fibres occurred at least ten years before the clinical onset of malignant neoplasm of the ovary;

(5) inhaling respirable asbestos fibres in an open environment:
   (a) for a cumulative period of at least 6 000 hours before the clinical onset of malignant neoplasm of the ovary; and
   (b) at the time material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled; and
   (c) where the first inhalation of respirable asbestos fibres occurred at least ten years before the clinical onset of malignant neoplasm of the ovary;

(6) for parous women only, an inability to breast feed for a cumulative period of at least six months before the clinical onset of malignant neoplasm of the ovary;
   Note: The period of breastfeeding could be cumulative over a number of pregnancies.

(7) for epithelial ovarian cancer only:
   (a) being nulliparous at the time of the clinical onset of malignant neoplasm of the ovary; or
   Note: *nulliparous* is defined in the Schedule 1 - Dictionary.
   (b) having hormone replacement therapy for at least five consecutive years before the clinical onset of malignant neoplasm of the ovary, and where the use of hormone replacement therapy has ceased, the clinical onset of malignant neoplasm of the ovary has occurred within ten years of that period;
   Note: *hormone replacement therapy* is defined in the Schedule 1 - Dictionary.

(8) for mucinous ovarian tumours only, smoking at least ten pack-years of cigarettes, or the equivalent thereof in other tobacco products, before the clinical onset of malignant neoplasm of the ovary, and:
   (a) smoking commenced at least ten years before the clinical onset of malignant neoplasm of the ovary; and
   (b) where smoking has ceased, the clinical onset of malignant neoplasm of the ovary, has occurred within 20 years of cessation;
Note: pack-years of cigarettes, or the equivalent thereof in other tobacco products is defined in the Schedule 1 - Dictionary.

(9) inability to obtain appropriate clinical management for malignant neoplasm of the ovary.

10 Relationship to service

(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.

(2) The factor set out in subsection 9(9) applies only to material contribution to, or aggravation of, malignant neoplasm of the ovary where the person's malignant neoplasm of the ovary was suffered or contracted before or during (but did not arise out of) the person's relevant service.

11 Factors referring to an injury or disease covered by another Statement of Principles

In this Statement of Principles:

(1) if a factor referred to in section 9 applies in relation to a person; and

(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(3) of the VEA;

then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.
1 Definitions

In this instrument:

**being obese** means having a Body Mass Index (BMI) of 30 or greater.

Note: BMI is also defined in the Schedule 1 - Dictionary.

**BMI** means \( \frac{W}{H^2} \) where:

- \( W \) is the person's weight in kilograms; and
- \( H \) is the person's height in metres.

**cumulative equivalent dose** means the total dose of ionising radiation received by the particular organ or tissue from external exposure, internal exposure or both, apart from normal background radiation exposure in Australia, calculated in accordance with the methodology set out in *Guide to calculation of 'cumulative equivalent dose' for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans' Entitlements Act 1986 (Cth)*, Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017.

Note 1: Examples of circumstances that might lead to exposure to ionising radiation include being present during or subsequent to the testing or use of nuclear weapons, undergoing diagnostic or therapeutic medical procedures involving ionising radiation, and being a member of an aircrew, leading to increased levels of exposure to cosmic radiation.

Note 2: For the purpose of dose reconstruction, dose is calculated as an average over the mass of a specific tissue or organ. If a tissue is exposed to multiple sources of ionising radiation, the various dose estimates for each type of radiation must be combined.

**hormone replacement therapy** means administration of estrogen preparations often in combination with progesterone to offset a hormone deficiency following surgically induced or naturally occurring menopause.

**malignant neoplasm of the ovary**—see subsection 7(2).

**MRCA** means the *Military Rehabilitation and Compensation Act 2004*.

**nulliparous** means never having experienced a gestation period of at least 20 weeks.

**pack-years of cigarettes, or the equivalent thereof in other tobacco products** means a calculation of consumption where one pack-year of cigarettes equals 20 tailor-made cigarettes per day for a period of one calendar year, or 7300 cigarettes. One tailor-made cigarette approximates one gram of tobacco or one gram of cigar or pipe tobacco by weight. One pack-year of tailor-made
cigarettes equates to 7.3 kilograms of smoking tobacco by weight. Tobacco products mean cigarettes, pipe tobacco or cigars, smoked alone or in any combination.

**relevant service** means:

(a) eligible war service (other than operational service) under the VEA;
(b) defence service (other than hazardous service and British nuclear test defence service) under the VEA; or
(c) peacetime service under the MRCA.

Note: MRCA and VEA are also defined in the Schedule 1 - Dictionary.

**terminal event** means the proximate or ultimate cause of death and includes the following:

(a) pneumonia;
(b) respiratory failure;
(c) cardiac arrest;
(d) circulatory failure; or
(e) cessation of brain function.

**VEA** means the Veterans' Entitlements Act 1986.
Endnotes

Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history

Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.
Statement of Principles concerning
Malignant Neoplasm Of The Ovary (Balance of Probabilities) (No. 10 of 2018)
Veterans’ Entitlements Act 1986

Compilation No. 1
Compilation date: 02/04/2018

Authorised Version F2018C00151 registered 13/03/2018
### Endnote 3—Legislation history

<table>
<thead>
<tr>
<th>Name</th>
<th>Registration</th>
<th>Commencement</th>
<th>Application, saving and transitional provisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statement of Principles concerning malignant neoplasm of the ovary No. 10 of 2018</td>
<td>2 January 2018</td>
<td>29 January 2018</td>
<td>F2018L00011</td>
</tr>
<tr>
<td>Amendment Statement of Principles concerning malignant neoplasm of the ovary No. 36 of 2018</td>
<td>5 March 2018</td>
<td>2 April 2018</td>
<td>F2018L00184</td>
</tr>
</tbody>
</table>
## Endnote 4—Amendment history

<table>
<thead>
<tr>
<th>Provision affected</th>
<th>How affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subsection 10(2)</td>
<td>rs Instrument No. 36 of 2018</td>
</tr>
</tbody>
</table>